Home / Results from a phase I study of AMG 160
Dr. Tran (AU) talked about his presentation “Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).”
